Jose Martinez, DO
Rheumatology · Altamonte Springs, FLNPI 1043654775
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $55,800 of the $71,892 with a category attached, or 77.6%. AbbVie accounts for 83.4% of it on its own, with 25 other manufacturers making up the rest. 2025 is the largest year on record at $20,687, 8.8 times the $2,339 reported in 2019. Among rheumatology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 601 payments — averaging $119.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$60K
- UCB, Inc.$3K
- Pfizer$2K
- Amgen$2K
- Novartis$620
- Lilly USA, LLC$573
- plus $3K from 20 others
Across 2 payments — averaging $4087.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$8K
What the payments were for
- Consulting fees$3,5155%
- Speaking & faculty fees$55,80078%
- Travel & lodging$1,5662%
- Food & beverage$10,79115%
- Education$2200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 142 | $59,982 |
| UCB, Inc. | 91 | $3,112 |
| Pfizer | 36 | $2,366 |
| Amgen(2 entities) | 117 | $2,149 |
| Novartis | 33 | $620 |
| Lilly USA, LLC | 32 | $573 |
| GSK | 28 | $482 |
| Johnson & Johnson(2 entities) | 23 | $420 |
| Mallinckrodt Hospital Products Inc. | 15 | $316 |
| E.r. Squibb & Sons, L.L.C. | 11 | $251 |
| AstraZeneca | 13 | $246 |
| Genentech USA, Inc. | 14 | $223 |
| Abbott | 2 | $215 |
| Radius Health, Inc. | 8 | $176 |
| ANI Pharmaceuticals, Inc. | 8 | $166 |
| Sanofi | 8 | $159 |
| Sobi, Inc | 9 | $154 |
| Medtronic | 1 | $93 |
| Bristol Myers Squibb | 2 | $35 |
| Boehringer Ingelheim | 2 | $34 |
| Fresenius Kabi USA, LLC | 1 | $29 |
| Mallinckrodt Enterprises LLC | 1 | $27 |
| Boston Scientific | 1 | $26 |
| Medline Industries LP | 1 | $14 |
| Antares Pharma, Inc. | 1 | $12 |
| Ultragenyx Pharmaceutical Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$71,892 in reported general payments places this provider in the 90th percentile of 453 rheumatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MethotrexateMethotrexate Sodium | 49 | $924 |
| Prednisone | 161 | $830 |
| Leflunomide | 17 | $650 |
| Gabapentin | 48 | $618 |
| Diclofenac Sodium | 64 | $584 |
| Hydroxychloroquine Sulfate | 45 | $522 |
| Celecoxib | 25 | $446 |
| Colchicine | 15 | $404 |
| Pregabalin | 13 | $277 |
| Baclofen | 14 | $178 |
| Cyclobenzaprine Hcl | 25 | $125 |
| Sulfasalazine | 12 | $79 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Altamonte Springs
- Alvin WellsDestin$2.4M
- Guillermo ValenzuelaPlantation$1.5M
- Julio Gonzalez-PaoliTampa$1.4M
- Ernesto RodriguezZephyrhills$958K
- Vinicius Costa Diniz DominguesDaytona Beach$921K
- Jonathan GreerBoynton Beach$757K
- Jigar ShahMargate$750K
- Rachel TateHollywood$729K
- Howard BuschLoxahatchee$717K
- Michael WeitzMiami$658K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.